Financial Report: Pfizer 3Q

Pfizer 3Q

3Q Revenues: $11.6 billion (-3%)

3Q Earnings: $2.9 billion (+26%)

YTD Revenues: $33.5 billion (-7%)

YTD Earnings: $7.9 billion (flat)

Comments: Total pharmaceutical sales in the quarter were $10.7 billion (-3%). Primary Care sales were down 4% to $5.5 billion. Specialty Care sales were up 3% to $1.6 billion. Oncology revenue was $371 million (-5%). Established Products revenue was $1.6 billion (-12%) and Emerging Markets revenue was $1.6 billion (-4%). U.S. revenues were $4.8 billion (-2%) in the quarter and international revenues were $6.8 billion (-4%). YTD U.S. revenues were $14.3 billion (-6%) and international revenues were $19.2 billion (-8%). Revenues in the quarter and YTD were unfavorably impacted by 5% and 6% respectively, due to foreign exchange. R&D expenses were down 13% to $1.6 billion in the quarter and down 11% to 5.0 billion YTD.